EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating α-Klotho Is Elevated in Breast Cancer and Positively Correlates with IGF-1

Shira Ben Neriah, Marana Abboud, Alla Berlin, Rina Hemi, Rona Aks, Shiran Shapira, Ido Wolf iD, Tami Rubinek iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27209257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Shira Ben Neriah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Breast Neoplasms, Glucuronidase, Carcinoma, Intraductal, Noninfiltrating. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most commonly diagnosed cancer among women worldwide. Klotho is an anti-aging protein implicated in tumor suppression; however, the relationship between circulating Klotho levels and BC remains unclear. We measured serum Klotho by enzyme-linked immunosorbent assay (ELISA) in 372 participants: 166 patients with BC, 24 patients with ductal carcinoma in situ (DCIS), and 182 controls, and examined its relation to clinicopathological characteristics, including estrogen receptor (ER), progesterone receptor (PR), HER2 and lymph node status, body mass index (BMI), and insulin-like growth factor 1 (IGF-1). Serum Klotho levels were significantly higher in invasive BC and DCIS patients compared with controls (p = 0.003 and p = 0.001, respectively), whereas no significant difference was detected between invasive BC and DCIS. After adjustment for age, Klotho levels remained significantly higher in BC and DCIS patients than in controls. Klotho levels correlated positively with IGF-1 (p = 0.0043), but not with BMI, ER, PR, HER2, or lymph node status. These preliminary findings demonstrate an association between elevated circulating Klotho and BC, as well as a positive relationship between Klotho and IGF-1. Further studies using age-matched cohorts and diagnostic-performance analyses are required to determine whether circulating Klotho has clinical utility as a BC biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Like Growth Factor IBreast NeoplasmsGlucuronidaseCarcinoma, Intraductal, NoninfiltratingHumansFemaleKlotho ProteinsMiddle AgedBiomarkers, TumorAgedAdultCase-Control StudiesErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

IGF-1Klothoagingbiomarkerbreast cancertumor suppressor

Substanzen

Insulin-Like Growth Factor IKlotho ProteinsGlucuronidaseKL protein, humanBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesIGF1 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Endocrinology Institute, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.

ORCID-Profile: Ido Wolf, Tami Rubinek

Zitieren

APA

Ben Neriah, S., Abboud, M., Berlin, A., Hemi, R., Aks, R., Shapira, S., Wolf, I., & Rubinek, T. (2026). Circulating α-Klotho Is Elevated in Breast Cancer and Positively Correlates with IGF-1. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209257

Vancouver

Ben Neriah S, Abboud M, Berlin A, Hemi R, Aks R, Shapira S, et al. Circulating α-Klotho Is Elevated in Breast Cancer and Positively Correlates with IGF-1. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209257

BibTeX
@article{BenNeriah2026,
  author = {Ben Neriah, Shira and Abboud, Marana and Berlin, Alla and Hemi, Rina and Aks, Rona and Shapira, Shiran and Wolf, Ido and Rubinek, Tami},
  title = {Circulating α-Klotho Is Elevated in Breast Cancer and Positively Correlates with IGF-1},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27209257}
}
Kostenlos starten →